An Interactive Case-Based Review of Chronic Lymphocytic Leukemia: Experts Explore the Latest Evidence and Guideline Updates

December 6, 2024

The goal of this activity is to improve learners’ knowledge, competence, and confidence to integrate new and emerging therapies into practice to improve clinical outcomes in patients with chronic lymphocytic leukemia / small lymphocytic lymphoma.

Target Audience

This program is intended for hematologists, oncologists, physician associates, nurses, pharmacists, and other healthcare professionals who care for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select first-line therapy for treatment-naive CLL/SLL, taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference
  • Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents used to treat CLL/SLL with the similar mechanism of action
  • Plan individualized treatment approaches for relapsed/refractory CLL/SLL, based on optimal sequencing strategies recommended in the NCCN Guidelines (e.g. assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for therapy)
  • Evaluate emerging data for CLL/SLL across the disease spectrum, including novel combinations, non-covalent reversible BTK inhibitors, and CAR T-cell therapy

You may also be interested in

Individualized Multidisciplinary CLL Care: Practical Application of Guidelines and Emerging Data
The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Additional information
Supporters: 

Supported by educational grants from AstraZeneca, BeiGene, and Lilly.

Course summary
Available credit: 
  • 2.00 AAPA Category 1 CME credit
  • 2.00 ACPE contact hours
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC contact hours
  • 2.00 Participation
Course opens: 
12/06/2024
Course expires: 
01/12/2025
Event starts: 
12/06/2024 - 10:30am EST
Event ends: 
12/06/2024 - 12:30pm EST
Cost:
$0.00
Add to calendar: 

Danielle M. Brander, MD
Assistant Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapy
Duke Cancer Institute
Durham, North Carolina

Brian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Sameer A. Parikh, MBBS
Consultant, Division of Hematology
Chair, CLL Disease Team
Vice Chair, Lymphoid Malignancies Disease Group
Mayo Clinic Comprehensive Cancer Center
Associate Professor of Medicine
Assistant Professor of Oncology
Mayo Clinic
Rochester, Minnesota

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Danielle M. Brander, MD
AbbVie, Inc.: Consultant/Advisor; Grant/Research Support
ArQule/Merck: Grant/Research Support 
Ascentage Pharma: Grant/Research Support
AstraZeneca/Acerta: Grant/Research Support 
BeiGene: Grant/Research Support 
Catapult Therapeutics: Grant/Research Support
DTRM: Grant/Research Support 
Genentech, Inc.: Consultant/Advisor; Grant/Research Support
Juno/Celgene/Bristol Myers Squibb: Grant/Research Support
MEI Pharma, Inc.: Grant/Research Support
Newave Pharmaceutical Co., Ltd.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support
Pharmacyclics: Consultant/Advisor; Grant/Research Support
TG Therapeutics, Inc.: Grant/Research Support

Brian T. Hill, MD, PhD
AstraZeneca Pharmaceuticals LP: Consultant/Advisor/Speaker
BeiGene: Consultant/Advisor/Speaker
Bristol Myers Squibb: Consultant/Advisor/Speaker
Genentech, Inc.: Consultant/Advisor/Speaker
Genmab/AbbVie: Consultant/Advisor/Speaker
Pharmacyclics: Consultant/Advisor/Speaker

Sameer A. Parikh, MBBS
AbbVie, Inc.: Consultant/Advisor
Amgen Inc.: Consultant/Advisor
AstraZeneca Pharmaceuticals LP: Consultant/Advisor; Grant/Research Support
BeiGene: Consultant/Advisor
Genentech, Inc.: Consultant/Advisor; Grant/Research Support
Janssen Pharmaceutica Products, LP: Consultant/Advisor; Grant/Research Support
Kite Pharma: Consultant/Advisor
Merck & Co., Inc.: Consultant/Advisor; Grant/Research Support
MingSight Pharmaceuticals, Inc: Consultant/Advisor
NovalGen: Consultant/Advisor
Pharmacyclics: Consultant/Advisor
TG Therapeutics, Inc.: Consultant/Advisor

NCCN/CCO Staff Disclosures

None of the other planners/managers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients. 

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 2.0 contact hours.

Pharmacists
NCCN designates this application-based continuing education activity for 2.0 contact hours (0.20 CEUs) of continuing education credit. UAN: JA4008196-0000-24-094-L01-P

PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.

For ABIM MOC points, your information will be shared with the ABIM through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to ABIM via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

Available Credit

  • 2.00 AAPA Category 1 CME credit
  • 2.00 ACPE contact hours
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC contact hours
  • 2.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to start the credit claiming process.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing